Arrowhead Pharmaceuticals, Inc. (ARWR): Price and Financial Metrics
ARWR Price/Volume Stats
| Current price | $24.82 | 52-week high | $41.28 |
| Prev. close | $25.00 | 52-week low | $20.67 |
| Day low | $24.47 | Volume | 70,688 |
| Day high | $25.00 | Avg. volume | 1,385,047 |
| 50-day MA | $27.02 | Dividend yield | N/A |
| 200-day MA | $28.59 | Market Cap | 3.08B |
ARWR Stock Price Chart Interactive Chart >
Arrowhead Pharmaceuticals, Inc. (ARWR) Company Bio
Arrowhead Pharmaceuticals is a biopharmaceutical company developing targeted RNAi therapeutics. The company was founded in 1989 and is based in Pasadena, California.
Latest ARWR News From Around the Web
Below are the latest news stories about ARROWHEAD PHARMACEUTICALS INC that investors may wish to consider to help them evaluate ARWR as an investment opportunity.
Arrowhead Pharmaceuticals Inc CEO Christopher Anzalone Sells 12,000 SharesArrowhead Pharmaceuticals Inc (NASDAQ:ARWR) CEO Christopher Anzalone sold 12,000 shares of the company's stock on December 20, 2023, according to a recent SEC filing. |
Arrowhead Pharmaceuticals Files for Regulatory Clearance to Initiate Phase 1/2a Study of ARO-CFB for Complement Mediated Kidney DiseasePASADENA, Calif., December 21, 2023--Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has filed an application for clearance to initiate a Phase 1/2a clinical trial of ARO-CFB, the company’s investigational RNA interference (RNAi) therapeutic being developed as a potential treatment for complement mediated renal disease, such as immunoglobulin A nephropathy (IgAN), which is the most common glomerular disease worldwide and carries a high lifetime risk of progression to end-st |
Arrowhead Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare ConferencePASADENA, Calif., December 20, 2023--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to present at the upcoming 42nd Annual J.P. Morgan Healthcare Conference on January 8, 2024, at 8:15 a.m. PT. |
ARWR: Updates on Plozasiran and Zodasiran at AHA 2023…By David Bautz, PhD NASDAQ:ARWR READ THE FULL ARWR RESEARCH REPORT Business Update Updated Clinical Data for Cardiometabolic Candidates Presented at AHA 2023 On November 13, 2023, Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR) announced new clinical data for the Phase 2 SHASTA-2 and MUIR studies of plozasiran (ARO-APOC3) and the ARCHES-2 study of zodasiran (ARO-ANG3) were presented at the American |
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Q4 2023 Earnings Call TranscriptArrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Q4 2023 Earnings Call Transcript November 29, 2023 Operator: Ladies and gentlemen, welcome to the Arrowhead Pharmaceuticals Conference Call. Throughout today’s recorded presentation, all participants will be in a listen-only. After the presentation, there will be an opportunity to ask questions. I will now hand the conference call over to Vince […] |
ARWR Price Returns
| 1-mo | -3.42% |
| 3-mo | -19.55% |
| 6-mo | -7.94% |
| 1-year | -38.67% |
| 3-year | -62.61% |
| 5-year | 27.22% |
| YTD | -18.89% |
| 2023 | -24.56% |
| 2022 | -38.82% |
| 2021 | -13.59% |
| 2020 | 20.97% |
| 2019 | 410.71% |
Continue Researching ARWR
Here are a few links from around the web to help you further your research on Arrowhead Pharmaceuticals Inc's stock as an investment opportunity:Arrowhead Pharmaceuticals Inc (ARWR) Stock Price | Nasdaq
Arrowhead Pharmaceuticals Inc (ARWR) Stock Quote, History and News - Yahoo Finance
Arrowhead Pharmaceuticals Inc (ARWR) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...